Market Outlook
The global liquid biopsy market, valued at USD 8.20 billion in 2025, is projected to reach USD 9.49 billion in 2026 and USD 33.45 billion by 2035, representing a CAGR of 15.0% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Market Report: Key Takeaways
Market Size & Trends
- In terms of type of technology, next-generation sequencing currently dominates (nearly 50%) the current market.
- With respect to type of sample, blood sub segment holds the highest market share (~90%) of the current market.
- Based on type of circulating biomarker, circulating tumor DNA captures the most (about 45%) of the current market.
- In terms of the type of cancer, breast cancer currently dominates (about 30%) the current market.
- With respect to application area, early diagnosis holds the highest market share (~70%) of the current market.
- Based on end-user, the hospitals / laboratories currently dominate (about 75%) the current market
- In terms of geographical regions, North America currently holds the highest market share (around 50%).
Key Market Statistics
- Market Size in 2026: $ 9.49 Billion
- Estimated Market Size in 2035: $ 33.45 Billion
- CAGR (2026-2035): 15.0%
- North America: Largest market in 2026
Market Introduction
Experts have long considered tissue biopsy the gold standard for cancer diagnosis. However, the limitations associated with this invasive procedure, such as discomfort, pain and risk of complications discourage patients from widely accepting this technique for cancer diagnosis. Over time, extensive research has enabled experts to recognize liquid biopsy as a viable technique for cancer detection.
Liquid biopsy solutions offer a minimally invasive and accessible method for early cancer detection and patient monitoring. These tests use blood samples or other bodily fluids, such as urine or plasma to identify genetic mutations and various circulating biomarkers, including circulating tumor DNA, cell free DNA and extracellular vesicles. These non-invasive tests are transforming cancer care, especially for patients with advanced cancer stages.
The market for liquid biopsy is growing rapidly and remains dynamic, with numerous companies investing heavily in research and development. These investments capitalize on scientific advancements in liquid biopsy industry, heralding a new era in cancer diagnostics within the oncology industry. With continuous innovation in this field, experts anticipate that the adoption of such liquid biopsy solutions and other non-invasive cancer diagnostics will increase significantly, which will drive market growth during the forecast period.
Market Segmentation
Based on our market research, we have segmented the liquid biopsy market forecast into type of technology, type of sample, type of circulating biomarker, type of cancer, application area, end-user, and geographical regions.
By Type of Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
By Type of Sample
By Type of Circulating Biomarker
- Circulating Tumor DNA
- Cell Free DNA
- Cell Free RNA
- Exosomes
- Other Circulating Biomarkers
By Type of Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate cancer
- Lung Cancer
- Bladder Cancer
- Melanoma
- Thyroid Cancer
- Gastric Cancer
- Head and Neck Cancer
- Leukemia
- Brain Cancer
- Liver Cancer
- Cervical Cancer
- Ovarian Cancer
- Oesophagus Cancer
- Pancreatic Cancer
- Nasopharyngeal cancer
- Sarcoma
By Application Area
- Early Diagnosis
- Patient Monitoring
- Recurrence Monitoring
By End-user
- Hospitals / Laboratories
- Research Institutes
- Other End-users
By Geographical Regions
- North America
- US
- Europe
- France
- UK
- Germany
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
Liquid Biopsy Market Key Insights
What are the Key Drivers for Liquid Biopsy Market Growth?
- Technological Advancements: Technological breakthroughs in next generation sequencing market and digital PCR have vastly improved the sensitivity and specificity of liquid biopsy assays. These technologies allow for the detection of extremely low concentrations of circulating tumor DNA and circulating tumor cells, enabling the identification of actionable genomic alterations that were previously undetectable without solid tissue samples.
- Integration of AI and Bioinformatics: The integration of artificial intelligence and machine learning algorithms has changed the interpretation of complex data derived from liquid biopsies. These tools enhance the signal-to-noise ratio, allowing for more accurate detection of epigenetic patterns. This computational support helps in reducing false positives and accelerating the speed of clinical decision-making.
- Demand for Real-Time Treatment Monitoring: Liquid biopsy provides a real-time genomic snapshot, allowing oncologists to monitor therapy response and detect cancer. By identifying resistance mutations early, clinicians can proactively adjust treatment protocols to improve patient outcomes.
What are the Main Challenges in Market Growth?
- High Research and Development Costs: The high capital requirement for research and development acts as a significant barrier. These costs often restrict market participation for smaller firms and delay the commercialization of novel diagnostic solutions.
- Data Integration and Interpretation Challenges: The high volume of data generated by NGS requires bioinformatics infrastructure. The lack of standardized protocols for data analysis and the clinical interpretation of variants can lead to inconsistencies in reporting, which hinders the widespread adoption of liquid biopsy in clinical practice.
Recent Developments in Liquid Biopsy Market
- In December 2025, DELFI Diagnostics collaborated with Hackensack Meridian Health to improve lung cancer screening adherence with innovative blood tests.
- In December 2025, Freenome merged with Perceptive Capital Solutions to accelerate commercial platform development of former company’s AI / ML-enabled multiomics platform.
- In December 2025, Pillar Biosciences and AstraZeneca collaborated with the aim to deliver rapid and cost-effective liquid biopsy testing, thereby facilitating the implementation of former company’s liquid biopsy panels to enable localized tumor profiling.
Industry Experts on Liquid Biopsy Market Trends
The market for liquid biopsy has a transformative future and is likely to remain progressive in the coming years.
Sergio Figueiras Gómez (Innovation Director of Bahia Software) stated, “I believe liquid biopsy holds great potential. Its evolution in future relies on establishing well-structured databases, information from diagnostic tools, technicians and the integration of symptoms with the recorder data reports. Creating a comprehensive database with organized data will pave the way for leveraging advanced technologies, such as machine learning and artificial intelligence in this domain, enabling us to extract valuable insights, aiding in treatment decisions and patient care. As a result, the integration of liquid biopsy into routine clinical practice will become more seamless and effective, driving better patient outcomes.”
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:
- Director, Mid-sized Company, US
- Innovation Director, Mid-sized Company, Spain
- Founder and Chief Executive officer, Small-sized Company, India
- Founder, President and Chief Technology Officer, Small-sized Company, US
- Former Strategic Technology Advisor, Small-sized Company, Australia
- Founder and Medical Director, Small-sized Company, Germany
- Chief Executive officer, Small-sized Company, Australia
- Chief Operating Officer and Co-Founder, Small-sized Company, Canada
- Chief Medical Officer, Mid-sized Company, US
- Chairman, Small-sized Company, US
- Former Sales and Marketing Manager, Small-sized Company, Italy
- Former Marketing Director, Mid-sized Company, Belgium
- Former Founder, Small-sized Company, US
- Former Chief Executive Officer, Mid-sized Company, US
- Founder, Small-sized Company, Sweden
- Former Chief Executive Officer and Co-founder, Small-sized Company, US
- Chief Scientific Officer, Mid-sized Company, US
Market Share Insights
Which Type of Technology Accounts for the Largest Share in the Liquid Biopsy Market?
- In 2026, next generation sequencing segment holds 52.7% of the overall market share. This is primarily because of their superior ability to perform high-throughput multi-gene profiling, the ongoing reduction in sequencing costs, and its high sensitivity in detecting rare genetic mutations for precision oncology.
- It is worth highlighting that next generation sequencing is anticipated to grow at a relatively faster pace (17.1%). The growing demand for high-throughput diagnostic solutions is driving the rapid adoption of this technology in clinical oncology.
Regional Analysis: Which Regions are Showing the Fastest Growth in Liquid Biopsy Testing Domain?
North America: Dominating the Market by Securing Highest Share
North America dominates the liquid biopsy solutions market and is likely to secure ~55% of the overall revenue share in 2026. It is important to highlight that the highly advanced pharmaceutical industry, strong regulatory frameworks, and the established presence of liquid biopsy solution providers is boosting the demand for liquid biopsy solutions in the region.
Which Type of Sample Accounts for the Largest Share in the Liquid Biopsy Market?
- According to the liquid biopsy market forecast, the blood segment accounts for ~89.5% of the overall market revenue. This is due to its minimally invasive nature and the well-established infrastructure for blood-based biomarker analysis in clinical settings.
Which Type of Circulating Biomarker Accounts for the Largest Share in the Liquid Biopsy Market?
- According to the liquid biopsy market forecast, the circulating tumor DNA segment accounts for 44.8% of the overall market revenue, currently. This can be attributed to its ability to provide real-time monitoring of tumor dynamics throughout the patient care cycle.
- In future, exosomes segment is likely to grow at a faster pace (16.5%), owing to their ability to carry diverse molecular components from living cells and its superior stability in various body fluids.
Which Type of Cancer Accounts for the Largest Share in the Liquid Biopsy Market?
- In 2026, breast cancer segment is likely to hold 28.8% of the overall market share. This is primarily due to the rising prevalence of breast cancer cases and the increasing adoption of non-invasive screening methods for early detection and treatment monitoring.
- It is worth highlighting that nasopharyngeal cancer is anticipated to grow at a relatively faster pace. This growth is driven by the high predictive value of plasma EBV DNA in monitoring treatment response and detecting minimal residual disease before clinical recurrence.
Which Application Area Accounts for the Largest Share in the Liquid Biopsy Market?
- According to the liquid biopsy market forecast, the early diagnosis segment accounts for 67.3% of the overall market revenue. This can be attributed to rising focus on early cancer detection to improve patient outcomes and reduce treatment costs.
- In future, early diagnosis segment is likely to grow at a faster pace owing to their ability to enable timely interventions that enhance survival rates and support personalized treatment plans.
Which End-user Accounts for the Largest Share in the Liquid Biopsy Market?
- Hospitals / laboratories segment holds 75.4% of the overall market share, according to the liquid biopsy market forecast. This is primarily due to their extensive testing volumes, skilled staff, and integration with standard diagnostic workflows.
- It is worth highlighting that hospitals / laboratories segment is anticipated to grow at a relatively faster pace. This growth is driven by expanding investments in advanced diagnostic tools and rising patients for comprehensive cancer screening.
Scope of Liquid Biopsy Market Report
| Key Report Attributes |
Details |
| Historical Trend |
Since 2021 |
| Forecast Period |
Till 2035 |
| Market Size 2026 |
$ 9.49 Billion |
| Market Size 2035 |
$ 33.45 Billion |
| CAGR (Till 2035) |
15.0% |
| Segments Covered |
- Type of Technology
- Type of Sample
- Type of Circulating Biomarker
- Type of Cancer
- Application Area
- End-user
- Geographical Regions
|
| Key Players |
(A complete list of companies captured is available in the report)
|
PowerPoint Presentation
(Complimentary) |
Available |
| Customization Scope |
15% Free Customization |
Excel Data Packs
(Complimentary) |
Available |
Frequently Asked Questions
Question 1: What is liquid biopsy?
Answer: A liquid biopsy is a non-invasive medical test that analyzes biological markers, such as DNA or cells from a tumour, found in a sample of blood or other body fluids.
Question 2: How big is the liquid biopsy market?
Answer: The liquid biopsy market size is anticipated to be worth USD 9.49 billion in 2026.
Question 3: What is the anticipated CAGR of liquid biopsy solutions market?
Answer: The global market is estimated to grow at an annualized CAGR of 15.0% during the forecast period.
Question 4: Which region is expected to witness the highest growth rate in liquid biopsy market?
Answer: Asia Pacific is likely to be the fastest growing market segment.
Question 5: How much does a liquid biopsy cost?
Answer: Liquid biopsy costs typically range from USD 600 to over USD 3,500, depending on whether the test is for early screening or comprehensive genomic profiling.
Question 6: Which liquid biopsy solutions are FDA approved?
Answer: Guardant360 CDx (Guardant Health), FoundationOne Liquid CDx (Foundation Medicine), cobas EGFR Mutation Test v2 (Roche), Galleri (GRAIL), and SimpleScreen CRC (Freenome).
Question 7: Which are very large liquid biopsy solution providers?
Answer: Bio-Rad Laboratories, Exact Sciences, Labcorp, Qiagen, Roche Diagnostics and Thermo Fisher Scientific.
